Synchrony dual-optic accommodating intraocular lens: Part 2: Pilot clinical evaluation
Accepted 29 August 2006.
Purpose
To evaluate the clinical outcomes of an accommodating dual-optic intraocular lens (IOL).
Setting
Private practice and university centers.
Methods
A prospective noncomparative case series with retrospective control comprised 21 patients (26 eyes) scheduled for small-incision extracapsular cataract extraction by phacoemulsification with implantation of the Synchrony dual-optic accommodating IOL (Visiogen) (accommodating IOL group) and 10 patients who had small-incision extracapsular phacoemulsification with implantation of a monofocal, single-optic IOL at least 6 months previously (control group). Patients were examined 1, 3, 6, and 12 months after surgery. Defocus curves in the accommodating IOL group were compared with those in the control group. The main outcome measures were postoperative distance uncorrected and best corrected visual acuity; near uncorrected, distance corrected, and near corrected visual acuity; and accommodative range based on defocus curves.
Results
Twenty-four eyes were available at the 6-month follow-up visit. All eyes had best corrected distance visual acuity of 20/40 or better, and 19 eyes (79%) had an uncorrected distance visual acuity of 20/40 or better. Uncorrected near visual acuity was 20/40 or better in all eyes. With distance correction, 23 eyes (96%) had an acuity of 20/40 or better at near. Defocus curve analysis suggested a mean accommodative range of 3.22 diopters (D) ± 0.88 (SD) (range 1.00 to 5.00 D) in the accommodating IOL group and 1.65 ± 0.58 D in the control group (range 1.00 to 2.50 D) (P<.05).
Conclusion
The Synchrony dual-optic IOL shows promise as an option to provide accommodative function in pseudophakic patients.
From the Department of Ophthalmology, Fundacion Oftalmologica de Santander (Ossma, Galvis), Bucaramanga, Colombia; Visiogen Inc. (Vargas), Irvine, California, and the Department of Ophthalmology, University of California San Francisco (Trager, Vagefi, McLeod), San Francisco, California, USA
Corresponding author: Stephen D. McLeod, MD, University of California San Francisco, Department of Ophthalmology, 10 Koret Way, K-304, San Francisco, California 94143, USA.
Supported in part by unrestricted grants from That Man May See, San Francisco, California, and Research to Prevent Blindness, New York, New York, USA.
Drs. Ossma, Galvis, Vagefi, and Trager have no financial or proprietary interest in any material or method mentioned. Drs. Vargas and McLeod have a financial interest in Visiogen Inc., and in the intraocular lens described.
ABSTRACT